CytoMed Therapeutics

Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a memorandum of understanding (MoU) with China’s Hangzhou CNK Therapeutics Co., Ltd. The agreement grants CytoMed a license to utilize CNK’s PiggyBac technology, enabling the permanent grafting of the Chimeric Antigen Receptor (CAR) gene into its…